Clinical trial
Optimal Treatment for Kidney Disease in HIV Infected Adults
NCT00089518 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Withdrawn
Key facts
| NCT number | NCT00089518 |
|---|---|
| Title | Optimal Treatment for Kidney Disease in HIV Infected Adults |
| Official title | A Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of an Angiotensin Receptor Blocker (Valsartan) and Highly Active Antiretroviral Therapy (HAART) Versus HAART Alone for the Treatment of HIV-Associated Nephropathy |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Withdrawn |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections, Kidney Disease |
| Intervention type | Drug |
| Interventions | Valsartan |
| Enrollment | 0 |
| First posted | Aug 6, 2004 |
| Last update posted | Mar 9, 2015 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: